US FDA News: FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

The FDA approved the first targeted therapy for adult patients with non-small cell lung cancer whose tumors have a genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.
Read more: FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy